Search

DE-102024132764-A1 - Composition for the treatment of a skin disease in an animal

DE102024132764A1DE 102024132764 A1DE102024132764 A1DE 102024132764A1DE-102024132764-A1

Abstract

The present invention relates to the technical field of veterinary medicinal products and specifically to a composition for the treatment of a skin disease in an animal. The main active ingredients of the composition are rapamycin, miconazole, and meloxicam in a mass ratio of (0.01–10):(0.1–20):(0.1–5) and a solvent mixture of water and polyethylene glycol in which the main active ingredients are soluble. The composition has considerable curative effects on fungal infections on the skin surfaces of animals, with low toxicity and minimal irritation.

Inventors

  • Wei Yang

Assignees

  • Longing Future Medical

Dates

Publication Date
20260513
Application Date
20241111

Claims (7)

  1. Composition for the treatment of a skin disease in an animal, the main active ingredients of which are rapamycin, miconazole and meloxicam in a mass ratio of (0.01 - 10):(0.1 - 20):(0.1 - 5), and a solvent mixture of water and polyethylene glycol in which the main active ingredients are soluble.
  2. Composition for the treatment of a skin disease in an animal after Claim 1 , wherein the mass ratio of rapamycin, miconazole and meloxicam is (0.1 - 8):(1 - 15):(0.5 - 3).
  3. Composition for the treatment of a skin disease in an animal after Claim 2 , wherein the mass ratio of rapamycin, miconazole and meloxicam is (1 - 5):(5 - 10):(1 - 3).
  4. Composition for the treatment of a skin disease in an animal following one of the Claims 1 until 3 , further comprising a pH regulator, an antiseptic, an anti-settling agent, a buffer, an osmotic pressure adjuster, an antioxidant, a surfactant and/or a transdermal penetration agent.
  5. Composition for the treatment of a skin disease in an animal after Claim 4 , wherein the buffer is selected from boric acid and its salt, phosphoric acid and its salt, acetic acid and its salt and/or citric acid and its salt.
  6. Composition for the treatment of a skin disease in an animal after Claim 4 , the anti-withdrawal agent being sucrose.
  7. Composition for the treatment of a skin disease in an animal following one of the Claims 1 , 3 , 5 and 6 , the composition being a dripping agent or a pouring agent.

Description

TECHNICAL AREA The present invention relates to the technical field of veterinary medicinal products and specifically to a composition for the treatment of a skin disease in an animal. BACKGROUND Although people's lives have improved in recent years, they face increased work pressure and a faster pace of life. For this reason, more and more animals, such as dogs and cats, are being kept as pets in people's homes. Skin diseases are among the most common clinical conditions in dogs and cats, accounting for approximately 20% of clinical cases. While the prognosis for skin diseases is generally not fatal, they are difficult to treat, with a high relapse rate and a long pathogenesis, and in some cases, they are even incurable. Skin diseases in small animals not only significantly impact their normal lives and health but can also be transmitted to humans, making the prevention and treatment of skin diseases in dogs and cats crucial. Skin diseases in dogs encompass all conditions that can cause itching, hair loss, crusting, and abnormal skin lesions. These diseases often have a high relapse rate, a long pathogenesis, and are difficult to categorize and diagnose. Skin diseases in dogs vary widely due to factors such as etiology, breed, age, individual differences, diet, environment, and stress. Treatment of skin diseases in dogs is complicated by formulation, timing of administration, incorrect routes of administration, or secondary infections. Fungal skin diseases in dogs are the most common skin diseases in small animals. Although the rate of fungal infection in dogs is relatively high, fungal skin diseases in dogs are generally not fatal, which is why they have not received sufficient attention in the past. With the improvement of human living conditions, the number of pets (dogs and cats) is increasing rapidly. Fungal skin diseases are also becoming common zoonoses that threaten the health and lives of both animals and humans, which is why they are receiving increasing attention. Fungal skin infections in dogs are the most common skin diseases in small animals. Although the rate of fungal infection in dogs is relatively high, fungal skin infections in dogs are usually not fatal, which is why they have not received enough attention in the past. With the improvement of human living conditions, the number of pets (dogs and cats) is increasing rapidly. Fungal skin infections are also becoming common zoonoses that threaten the health and lives of animals and humans, which is why they are receiving increasing attention. Commonly used antifungal agents currently include mainly azoles, polyenes, allylamines, and nucleic acid inhibitors. Drug resistance and side effects have become two major challenges in the treatment of fungal infections. Drug combinations are an important treatment for fungal infections, addressing both the reduction of resistance and the need for precise drug dosage and side effects. Currently, various topical antifungal agents are available, but most are ineffective or require long-term administration. BRIEF DESCRIPTION OF THE INVENTION The present invention relates to a composition for the treatment of a skin disease in an animal, the main active ingredients of which are rapamycin, miconazole and meloxicam in a mass ratio of (0.01 - 10):(0.1 - 20):(0.1 - 5), and a solvent mixture of water and polyethylene glycol in which the main active ingredients are soluble. According to some embodiments, the mass ratio of rapamycin, miconazole and meloxicam is (0.1 - 8):(1 - 15):(0.5 - 3). According to some embodiments, the mass ratio of rapamycin, miconazole and meloxicam is (1 - 5):(5 - 10):(1 - 3). According to some embodiments, the composition for treating a skin disease in an animal further comprises a pH regulator, an antiseptic, an anti-settling agent, a buffer, an osmotic pressure adjusting agent, an antioxidant, a surfactant and/or a transdermal penetration agent. The pH regulator adjusts the pH of the medication to closely match or approximate the pH of a pet's skin. The concentration of the pH regulator ranges from 0.01% to 5% and is adjusted depending on the specific medication. The pH regulator may contain citric acid, hydrochloric acid, phosphoric acid, benzoic acid, sodium hydroxide, and/or potassium hydroxide. Examples of pH regulator concentrations are 0.01%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, and 5%. The antioxidant concentration ranges from 0.01% to 5%, and the antioxidant can prevent or delay oxidation and improve the stability of the drug. The antioxidant includes tocopherol, butylhydroxyanisole, dibutylhydroxytoluene, and/or tert-butylhydroquinone. Examples of antioxidant concentrations are 0.01%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 1%, 2%, 3%, 4%, and 5%. The transdermal penetration agent consists of propylene glycol, laurocapram, caprylic/capric triglyceride, and/or diethylene glycol monoethyl ether. Propylene glycol can be used both as a solvent and as a transdermal penetration agent and sho